- July 29, 2019
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical to Participate in READYFOR SDGs, Using Crowd Funding to Support Organizations Addressing Issues in the Field of Oncology
Taiho Pharmaceutical Co., Ltd. today announced that it will participate in READYFOR SDGs, a matching program for corporate SDGs provided by READYFOR, Inc. READYFOR SDGs uses the crowd funding service Readyfor to match corporations working to help achieve Sustainable Development Goals (SDGs) with ambitious organizations and activities, with the aim of co-creating social value in the various fields targeted by the SDGs.
By participating in READYFOR SDGs, Taiho Pharmaceutical hopes to contribute to the achievement of the SDGs by practicing co-creation with organizations and individuals striving to address issues in the field of oncology, which falls under Goal 3 of the SDGs: “Good Health and Well-Being.”
Taiho Pharmaceutical plans to provide matching gifts totaling 10 million yen and will begin accepting project funding applications in September 2019.
See the following website (Japanese only) for details about READYFOR SDGs. https://sdgs.readyfor.jp/
In line with its corporate philosophy—“We strive to improve human health and contribute to a society enriched by smiles”—Taiho Pharmaceutical’s entire team is working as one to pursue sustainability in order to ensure that the company remains a valuable contributor to the health of people worldwide by developing and supplying innovative pharmaceuticals.
READYFOR, Inc. runs the first and one of the largest crowdfunding services in Japan, Readyfor. Its mission is to “Create a world where everyone can realize what they want.” Since March 2011, when Readyfor was started, a total of US$80 million has been pledged by 580,000 people. The company’s Readyfor service supports a variety of people, from elementary school students to adults in their 80s and up, to get closer to their dreams. (Information as of July 2019)
Information in this news release was current as of the original release date.